InsightfulValue
โ† Home

Gilead Sciences
Gilead Sciences

Pharma / Pharma


๐Ÿ”ง Tools

โœ… Due Diligence
๐Ÿ“ข Press Releases

Date Press release
2025-05-23 08:30:00 Ascent-03: Trodelvyยฎ Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement In Progression Free Survival In Patients With First-line Metastatic Triple-negative Breast Cancer Who Are Not Candidates For Checkpoint Inhibitors
Foster city, calif.--(business wire)--gilead sciences, inc. (nasdaq: gild) today announced positive topline results from the phase 3 ascent-03 study of trodelvyยฎ (sacituzumab govitecan-hziy). the study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (pfs) compared to chemotherapy in patients with first-line metastatic triple-negative breast cancer (mtnbc) who are not candidates for pd-1/pd-l1 inhibitor.
2025-05-15 16:15:00 Gilead And Kite Announce Presentation Of Transformative Data In 1l Metastatic Triple-negative Breast Cancer, Updated Results In Multiple Myeloma And Early Data From Novel Investigational Car T-cell Therapy Targeting Brain Cancer At 2025 Asco And Eha
Foster city, calif. & santa monica, calif.--(business wire)--gilead sciences, inc. (nasdaq: gild) will present more than 20 abstracts across both gilead and kite at the upcoming 2025 american society of clinical oncology (asco) annual meeting may 30 โ€“ june 3 and the 2025 european hematology association (eha) annual congress june 12 โ€“ 15. the studies span breast cancer and other solid tumors (glioblastoma, endometrial cancer, lung cancer, gastric cancer), as well as multiple blood cancers (multi.
2025-05-07 02:30:00 Final Data From The Phase 3 Myr301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment
Foster city, calif.--(business wire)--gilead sciences inc. (nasdaq: gild) today announced final results from the pivotal phase 3 myr301 study revealing that 36% (23 out of 64) of adults living with chronic hepatitis delta virus (hdv) treated with the first-in-class entry inhibitor bulevirtide at either a 2 mg or 10 mg dose maintained virologic suppression for almost two years after stopping treatment after achieving undetectable hdv rna at end of treatment (eot). in participants who sustained u.
2025-05-07 02:15:00 Gileadโ€™s Livdelziยฎ (seladelpar) Demonstrated Consistent Efficacy And Safety Regardless Of Prior Treatment History In New Data Presented At Easl 2025
Foster city, calif.--(business wire)--gilead sciences, inc. (nasdaq: gild) today announced new data from multiple analyses which reinforce that livdelziยฎ (seladelpar), known as lyvdelziยฎ in the european union, is effective and generally well-tolerated for the treatment of primary biliary cholangitis (pbc) and also provides sustained biochemical response in adults with pbc regardless of prior treatment history. another analysis provides evidence supporting that livdelzi delivered clinically and.
2025-04-29 16:05:00 Gilead Sciences To Present At Upcoming Investor Conferences
Foster city, calif.--(business wire)-- #gild--gilead sciences, inc. (nasdaq: gild) announced today that its executives will be speaking at the following investor conferences: bofa securities health care conference on tuesday, may 13 at 11:20 am pacific time rbc capital markets global healthcare conference on wednesday, may 21 at 11:30 am eastern time bernstein annual strategic decisions conference on thursday, may 29 at 2:30 pm eastern time jefferies global healthcare conference on wednesday, june 4 at.
2025-04-29 08:30:00 R2lsZWFkIF RvIFByZXNl bnQgTGF0ZX N0IEFkdmFu Y2VtZW50cy BBY3Jvc3Mg UHJpbWFyeS BCaWxpYXJ5 IENob2xhbm dpdGlzIEFu ZCBWaXJhbC BIZXBhdGl0 aXM=
Rm9zdGVyIG NpdHksIGNh bGlmLi0tKG J1c2luZXNz IHdpcmUpLS 1naWxlYWQg c2NpZW5jZX MsIGluYy4g KG5hc2RhcT pnaWxkKSB0 b2RheSBhbm 5vdW5jZWQg bmV3IHJlc2 VhcmNoIHRv IGJlIHByZX NlbnRlZCBh dCB0aGUgZX Vyb3BlYW4g YXNzb2NpYX Rpb24gZm9y IHRoZSBzdH VkeSBvZiB0 aGUgbGl2ZX IgKGVhc2wp IGNvbmdyZX NzLCBtYXkg Ny0xMCwgMj AyNSwgYW1z dGVyZGFtLC BmdXJ0aGVy aW5nIGdpbG VhZOKAmXMg Y29tbWl0bW VudCB0byB0 cmFuc2Zvcm 0gdGhlIGxp dmVzIG9mIH Blb3BsZSBs aXZpbmcgd2 l0aCBsaXZl ciBkaXNlYX NlLiBuZXcg ZGF0YSB0by BiZSBwcmVz ZW50ZWQgYX QgZWFzbCB3 aWxsIGluY2 x1ZGUgYSBz dWJncm91cC BhbmFseXNp cyBmcm9tIG Fzc3VyZSwg YW4gb25nb2 luZyBvcGVu LWxhYmVsIH N0dWR5LCBh bmQgYW4gYW 5hbHlzaXMg b2YgdGhlIH BoYXNlIDMg cmVzcG9uc2 UgdHJpYWwg YW5kIHRoZS BvcGVuLWxh YmVsIGV4dG Vuc2lvbi4g ZGF0YSB3Lg ==
2025-04-24 16:02:00 R2lsZWFkIF NjaWVuY2Vz IEFubm91bm NlcyBGaXJz dCBRdWFydG VyIDIwMjUg RmluYW5jaW FsIFJlc3Vs dHM=
Rm9zdGVyIG NpdHksIGNh bGlmLi0tKG J1c2luZXNz IHdpcmUpLS 0gI2Vhcm5p bmdzLS1naW xlYWQgc2Np ZW5jZXMsIG luYy4gKG5h c2RhcTogZ2 lsZCkgYW5u b3VuY2VkIH RvZGF5IGl0 cyBmaXJzdC BxdWFydGVy IDIwMjUgcm VzdWx0cyBv ZiBvcGVyYX Rpb25zLiDi gJxnaWxlYW QgaGFkIGEg c3Ryb25nIH N0YXJ0IHRv IHRoZSB5ZW FyIGRyaXZl biBieSBleG NlbGxlbnQg Y29tbWVyY2 lhbCBhbmQg Y2xpbmljYW wgZXhlY3V0 aW9uIGFsb2 5nIHdpdGgg ZGlzY2lwbG luZWQgZXhw ZW5zZSBtYW 5hZ2VtZW50 LOKAnSBzYW lkIGRhbmll bCBv4oCZZG F5LCBnaWxl YWTigJlzIG NoYWlybWFu IGFuZCBjaG llZiBleGVj dXRpdmUgb2 ZmaWNlci4g 4oCcb3VyIG Jhc2UgYnVz aW5lc3MgZ3 JldyA0JSB5 ZWFyLW92ZX IteWVhciwg cHJpbWFyaW x5IGxlZCBi eSBiaWt0YX J2eeKAmXMg Y29udGludW VkIHN0cmVu Z3RoLCBhbm Qgd2UgYW5u b3VuY2VkIH Bvc2l0aXZl IHRvcGxpbm UgcGhhc2Ug MyByZXN1bH RzIGZvciB0 cm9kZWx2eS BwbHVzLg==
2025-04-10 16:05:00 R2lsZWFkIF NjaWVuY2Vz IFRvIFJlbG Vhc2UgRmly c3QgUXVhcn RlciAyMDI1 IEZpbmFuY2 lhbCBSZXN1 bHRzIE9uIF RodXJzZGF5 LCBBcHJpbC AyNCwgMjAy NQ==
Rm9zdGVyIG NpdHksIGNh bGlmLi0tKG J1c2luZXNz IHdpcmUpLS 0gI2Vhcm5p bmdzLS1naW xlYWQgc2Np ZW5jZXMsIG luYy4gKG5h c2RhcTogZ2 lsZCkgYW5u b3VuY2VkIH RvZGF5IHRo YXQgaXRzIG ZpcnN0IHF1 YXJ0ZXIgMj AyNSBmaW5h bmNpYWwgcm VzdWx0cyBh bmQgZ3VpZG FuY2Ugd2ls bCBiZSByZW xlYXNlZCBv biB0aHVyc2 RheSwgYXBy aWwgMjQsID IwMjUgYWZ0 ZXIgdGhlIG 1hcmtldCBj bG9zZXMuIG F0IDQ6MzAg cC5tLiBlYX N0ZXJuIHRp bWUgdGhhdC BkYXksIGdp bGVhZOKAmX MgbWFuYWdl bWVudCB3aW xsIGhvc3Qg YSB3ZWJjYX N0IHRvIGRp c2N1c3MgdG hlIGNvbXBh bnnigJlzIG ZpcnN0IHF1 YXJ0ZXIgMj AyNSBmaW5h bmNpYWwgcm VzdWx0cyBh bmQgcHJvdm lkZSBhIGJ1 c2luZXNzIH VwZGF0ZS4g YSBsaXZlIH dlYmNhc3Qg d2lsbCBiZS BhdmFpbGFi bGUgaW4gdG hlIGludmVz dG9ycyBzZW N0aW9uIG9m IHd3dy5naW xlYWQuY29t IGFuZCB3aW xsIGJlIGFy Y2hpdmVkIH RoZXJlIGZv ciBvbmUu
2025-03-12 08:30:00 R2lsZWFkIF ByZXNlbnRz IE5ldyBIaX YgVHJlYXRt ZW50IEFuZC BDdXJlIFJl c2VhcmNoIE RhdGEgQXQg Q3JvaSAyMD I1LCBJbmNs dWRpbmcgQW 4gSW52ZXN0 aWdhdGlvbm FsIExvbmct YWN0aW5nLC BUd2ljZS15 ZWFybHkgVG hlcmFweSBP cHRpb24=
Rm9zdGVyIG NpdHksIGNh bGlmLi0tKG J1c2luZXNz IHdpcmUpLS 1naWxlYWQg c2NpZW5jZX MsIGluYy4g KG5hc2RhcT ogZ2lsZCkg dG9kYXkgYW 5ub3VuY2Vk IHRoZSBwcm VzZW50YXRp b24gb2YgbG F0ZS1icmVh a2luZyBkYX RhIGFuZCBt dWx0aXBsZS BvcmFsIHBy ZXNlbnRhdG lvbnMgZnJv bSBpdHMgaW 5ub3ZhdGl2 ZSBoaXYgdH JlYXRtZW50 IHBvcnRmb2 xpbyBhbmQg cGlwZWxpbm UgYXQgdGhl IGNvbmZlcm VuY2Ugb24g cmV0cm92aX J1c2VzIGFu ZCBvcHBvcn R1bmlzdGlj IGluZmVjdG lvbnMgKGNy b2kgMjAyNS kuIHRoZSBu ZXcgZmluZG luZ3MgcmVm bGVjdCBhIH RyYW5zZm9y bWF0aXZlIH BvcnRmb2xp byBhbmQgYS ByYXBpZGx5 IGFkdmFuY2 luZyBmb3J3 YXJkLWxvb2 tpbmcgcGlw ZWxpbmUgZm 9jdXNlZCBv biBleHBhbm RpbmcgY2hv aWNlcyBhbm QgZW5oYW5j aW5nIG91dG NvbWVzIGZv ciB0aG9zZS B3aXRoIGhp diwgd2hpbG UgY29udGlu dWluZyB0by ByZWFjaCB0 b3dhci4=
2025-03-11 13:37:00 Rmlyc3QgQ2 xpbmljYWwg RGF0YSBGb3 IgR2lsZWFk 4oCZcyBJbn Zlc3RpZ2F0 aW9uYWwgT2 5jZS15ZWFy bHkgTGVuYW NhcGF2aXIg Rm9yIEhpdi BQcmV2ZW50 aW9uIFByZX NlbnRlZCBB dCBDcm9pID IwMjUgQW5k IFB1Ymxpc2 hlZCBJbiBU aGUgTGFuY2 V0
Rm9zdGVyIG NpdHksIGNh bGlmLi0tKG J1c2luZXNz IHdpcmUpLS 1naWxlYWQg c2NpZW5jZX MsIGluYy4g KG5hc2RhcT ogZ2lsZCkg dG9kYXkgcH Jlc2VudGVk IHRoZSBmaX JzdCBkYXRh IGZyb20gaX RzIG9uZ29p bmcgcGhhc2 UgMSBzdHVk eSBpbnZlc3 RpZ2F0aW5n IHR3byBub3 ZlbCwgb25j ZS15ZWFybH kgZm9ybXVs YXRpb25zIG 9mIGxlbmFj YXBhdmlyLC B0aGUgY29t cGFueeKAmX MgaW5qZWN0 YWJsZSBoaX YtMSBjYXBz aWQgaW5oaW JpdG9yLCBm b3IgdGhlIG ludmVzdGln YXRpb25hbC B1c2Ugb2Yg aGl2IHByZX ZlbnRpb24g YXMgcHJlLW V4cG9zdXJl IHByb3BoeW xheGlzIChw cmVwKS4gdG hlIGRhdGEg d2VyZSBwcm VzZW50ZWQg ZHVyaW5nIG FuIG9yYWwg YWJzdHJhY3 Qgc2Vzc2lv biBhdCB0aG UgY29uZmVy ZW5jZSBvbi ByZXRyb3Zp cnVzZXMgYW 5kIG9wcG9y dHVuaXN0aW MgaW5mZWN0 aW9ucyAoY3 JvaSAyMDI1 KSBhbmQgd2 VyZSBhbHNv IHB1Ymxpc2 hlZCB0b2Rh eSBpbiB0Lg ==
2025-02-24 08:30:00 RXVyb3BlYW 4gTWVkaWNp bmVzIEFnZW 5jeSBWYWxp ZGF0ZXMgR2 lsZWFk4oCZ cyBNYXJrZX RpbmcgQXV0 aG9yaXphdG lvbiBBcHBs aWNhdGlvbi BBbmQgRXUt bWVkaWNpbm VzIEZvciBB bGwgQXBwbG ljYXRpb24g Rm9yIFR3aW NlLXllYXJs eSBMZW5hY2 FwYXZpciBG b3IgSGl2IF ByZXZlbnRp b24=
Rm9zdGVyIG NpdHksIGNh bGlmLi0tKG J1c2luZXNz IHdpcmUpLS 1naWxlYWQg c2NpZW5jZX MsIGluYy4g KG5hc2RhcT ogZ2lsZCkg dG9kYXkgYW 5ub3VuY2Vk IHRoYXQgdG hlIGV1cm9w ZWFuIG1lZG ljaW5lcyBh Z2VuY3kgKG VtYSkgaGFz IHZhbGlkYX RlZCBmb3Ig cGFyYWxsZW wgYWNjZWxl cmF0ZWQgcm V2aWV3IHRo ZSBjb21wYW 554oCZcyBt YXJrZXRpbm cgYXV0aG9y aXphdGlvbi BhcHBsaWNh dGlvbiAobW FhKSBhbmQg ZXUtbWVkaW NpbmVzIGZv ciBhbGwgKG V1LW00YWxs KSBhcHBsaW NhdGlvbiBm b3IgbGVuYW NhcGF2aXLi gJR0aGUgY2 9tcGFueeKA mXMgdHdpY2 UteWVhcmx5 IGluamVjdG FibGUgaGl2 LTEgY2Fwc2 lkIGluaGli aXRvcuKAlG ZvciB0aGUg cHJldmVudG lvbiBvZiBo aXYgYXMgcH JlLWV4cG9z dXJlIHByb3 BoeWxheGlz IChwcmVwKS 4gYmFzZWQg b24gdGhlIG Fzc2Vzc21l bnQgb2YgZW 1h4oCZcyBj b21taXR0ZW UgZm9yIG1l ZGljaW5hbC Bwcm9kdWN0 cyBmb3IgaH VtYW4gdXMu
2025-02-20 16:30:00 R2lsZWFk4o CZcyBTZWxh ZGVscGFyIE dyYW50ZWQg Q29uZGl0aW 9uYWwgRXVy b3BlYW4gTW Fya2V0aW5n IEF1dGhvcm l6YXRpb24g Rm9yIFRoZS BUcmVhdG1l bnQgT2YgUH JpbWFyeSBC aWxpYXJ5IE Nob2xhbmdp dGlz
Rm9zdGVyIG NpdHksIGNh bGlmLi0tKG J1c2luZXNz IHdpcmUpLS 1naWxlYWQg c2NpZW5jZX MsIGluYy4g KG5hc2RhcT ogZ2lsZCkg dG9kYXkgYW 5ub3VuY2Vk IHRoYXQgdG hlIGV1cm9w ZWFuIGNvbW 1pc3Npb24g KGVjKSBoYX MgZ3JhbnRl ZCBjb25kaX Rpb25hbCBt YXJrZXRpbm cgYXV0aG9y aXphdGlvbi Bmb3Igc2Vs YWRlbHBhci Bmb3IgdGhl IHRyZWF0bW VudCBvZiBw cmltYXJ5IG JpbGlhcnkg Y2hvbGFuZ2 l0aXMgKHBi YykgaW4gY2 9tYmluYXRp b24gd2l0aC B1cnNvZGVv eHljaG9saW MgYWNpZCAo dWRjYSkgaW 4gYWR1bHRz IHdobyBoYX ZlIGFuIGlu YWRlcXVhdG UgcmVzcG9u c2UgdG8gdW RjYSBhbG9u ZSwgb3IgYX MgbW9ub3Ro ZXJhcHkgaW 4gdGhvc2Ug dW5hYmxlIH RvIHRvbGVy YXRlIHVkY2 EuIHNlbGFk ZWxwYXIgKG FuIG9ycGhh biBkZXNpZ2 5hdGVkIHBy b2R1Y3QpIG lzIG5vdyBh cHByb3ZlZC BhbmQgd2ls bCBwcm92aW RlIGFuIGlt cG9ydGFudC B0cmVhdG1l bnQgby4=
2025-02-19 16:05:00 R2lsZWFkIF NjaWVuY2Vz IFRvIFByZX NlbnQgQXQg VXBjb21pbm cgSW52ZXN0 b3IgQ29uZm VyZW5jZXM=
Rm9zdGVyIG NpdHksIGNh bGlmLi0tKG J1c2luZXNz IHdpcmUpLS 0gI2dpbGQt LWdpbGVhZC BzY2llbmNl cywgaW5jLi AobmFzZGFx OiBnaWxkKS Bhbm5vdW5j ZWQgdG9kYX kgdGhhdCBp dHMgZXhlY3 V0aXZlcyB3 aWxsIGJlIH NwZWFraW5n IGF0IHRoZS Bmb2xsb3dp bmcgaW52ZX N0b3IgY29u ZmVyZW5jZX M6IHRkIGNv d2VuIGFubn VhbCBoZWFs dGggY2FyZS Bjb25mZXJl bmNlIG9uIH R1ZXNkYXks IG1hcmNoID QgYXQgMTE6 MTAgYW0gZW FzdGVybiB0 aW1lIGxlZX JpbmsgcGFy dG5lcnMgZ2 xvYmFsIGhl YWx0aGNhcm UgY29uZmVy ZW5jZSBvbi B0dWVzZGF5 LCBtYXJjaC AxMSBhdCAx MDo0MCBhbS BlYXN0ZXJu IHRpbWUgdG hlIGxpdmUg d2ViY2FzdH MgY2FuIGJl IGFjY2Vzc2 VkIGF0IHRo ZSBjb21wYW 554oCZcyBp bnZlc3Rvcn MgcGFnZSBh dCBpbnZlc3 RvcnMuZ2ls ZWFkLmNvbS 4gdGhlIHJl cGxheXMgd2 lsbCBiZSBh dmFpbGFibG UgZm9yIGF0 IGxlYXN0ID MwIGRheXMg Zm9sbG93aW 5nIHRoZS4=
2025-02-18 08:30:00 VS5zLiBGZG EgQWNjZXB0 cyBHaWxlYW TigJlzIE5l dyBEcnVnIE FwcGxpY2F0 aW9ucyBGb3 IgVHdpY2Ut eWVhcmx5IE xlbmFjYXBh dmlyIEZvci BIaXYgUHJl dmVudGlvbi BVbmRlciBQ cmlvcml0eS BSZXZpZXc=
Rm9zdGVyIG NpdHksIGNh bGlmLi0tKG J1c2luZXNz IHdpcmUpLS 1naWxlYWQg c2NpZW5jZX MsIGluYy4g KG5hc2RhcT ogZ2lsZCkg dG9kYXkgYW 5ub3VuY2Vk IHRoYXQgdG hlIHUucy4g Zm9vZCBhbm QgZHJ1ZyBh ZG1pbmlzdH JhdGlvbiAo ZmRhKSBoYX MgYWNjZXB0 ZWQgaXRzIG 5ldyBkcnVn IGFwcGxpY2 F0aW9uIChu ZGEpIHN1Ym 1pc3Npb25z IGZvciBsZW 5hY2FwYXZp cuKAlHRoZS Bjb21wYW55 4oCZcyB0d2 ljZS15ZWFy bHkgaW5qZW N0YWJsZSBo aXYtMSBjYX BzaWQgaW5o aWJpdG9y4o CUZm9yIHRo ZSBwcmV2ZW 50aW9uIG9m IGhpdiBhcy BwcmUtZXhw b3N1cmUgcH JvcGh5bGF4 aXMgKHByZX ApLiB0aGUg ZmRhIHdpbG wgcmV2aWV3 IHRoZSBhcH BsaWNhdGlv bnMgdW5kZX IgcHJpb3Jp dHkgcmV2aW V3IGFuZCBo YXMgYXNzaW duZWQgYSBw cmVzY3JpcH Rpb24gZHJ1 ZyB1c2VyIG ZlZSBhY3Qg KHBkdWZhKS B0YXJnZXQg YWN0aW9uIG RhdGUgb2Yg anVuZSAxOS wgMjAyNS4g YWNjZXB0YW 5jZS4=
2025-02-11 16:05:00 R2lsZWFkIF NjaWVuY2Vz IEFubm91bm NlcyAyLjYg UGVyY2VudC BJbmNyZWFz ZSBJbiBGaX JzdCBRdWFy dGVyIDIwMj UgRGl2aWRl bmQ=
Rm9zdGVyIG NpdHksIGNh bGlmLi0tKG J1c2luZXNz IHdpcmUpLS 0gI2Rpdmlk ZW5kLS1naW xlYWQgc2Np ZW5jZXMsIG luYy4gKG5h c2RhcTogZ2 lsZCkgdG9k YXkgYW5ub3 VuY2VkIHRo YXQgdGhlIG NvbXBhbnni gJlzIGJvYX JkIG9mIGRp cmVjdG9ycy BoYXMgZGVj bGFyZWQgYW 4gaW5jcmVh c2Ugb2YgMi 42JSBpbiB0 aGUgY29tcG FueeKAmXMg cXVhcnRlcm x5IGNhc2gg ZGl2aWRlbm QsIGJlZ2lu bmluZyBpbi B0aGUgZmly c3QgcXVhcn RlciBvZiAy MDI1LiB0aG UgaW5jcmVh c2Ugd2lsbC ByZXN1bHQg aW4gYSBxdW FydGVybHkg ZGl2aWRlbm Qgb2YgJDAu NzkgcGVyIH NoYXJlIG9m IGNvbW1vbi BzdG9jay4g dGhlIGRpdm lkZW5kIGlz IHBheWFibG Ugb24gbWFy Y2ggMjgsID IwMjUsIHRv IHN0b2NraG 9sZGVycyBv ZiByZWNvcm QgYXQgdGhl IGNsb3NlIG 9mIGJ1c2lu ZXNzIG9uIG 1hcmNoIDE0 LCAyMDI1Li BmdXR1cmUg ZGl2aWRlbm RzIHdpbGwg YmUgc3Viam VjdCB0byBi b2FyZCBhcH Byb3ZhbC4g YWJvdXQu
Gilead Sciences

๐Ÿ“ฐ Browse additional press releases for Gilead Sciences!

Sign up for free or log in

๐ŸŽ Free download! "The Checklist Value Investor โ€” A Smarter Way to Pick Stocks"

© 2024 - 2025 InsightfulValue.com. All rights reserved. Newsletter
Legal